BJU International最新文献

{"title":"A prospective study of minimal residual disease in urological cancers using circulating tumour DNA","authors":"Arnav Srivastava, Derrian Cooley, Steven M. Monda, Ulka N. Vaishampayan, Samuel D. Kaffenberger, Lindsey A. Herrel, Jeffrey S. Montgomery, Khaled Hafez, Aaron M. Udager, Zachery R. Reichert, D. Bryan Johnson, Daniel R. Rhodes, Scott A. Tomlins, Todd M. Morgan","doi":"10.1111/bju.16890","DOIUrl":"https://doi.org/10.1111/bju.16890","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"8 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of microsurgical varicocelectomy on sperm capacitation and birth outcomes.","authors":"Manish Kuchakulla,Aaron A Gurayah,Jessica A Marinaro,Aaron Brant,Christopher D Gaffney,Philip Xie,Nahid Punjani,Caroline Kang,Jonathan Gal,Gianpiero D Palermo,James A Kashanian","doi":"10.1111/bju.16888","DOIUrl":"https://doi.org/10.1111/bju.16888","url":null,"abstract":"OBJECTIVETo assess the impact of microsurgical subinguinal varicocelectomy on sperm capacitation, semen parameters, pregnancy rates, and live birth outcomes in men with clinical varicoceles.PATIENTS AND METHODSWe retrospectively reviewed 260 consecutive men with clinical varicoceles who underwent a microsurgical subinguinal varicocelectomy procedure by a single surgeon from January 2019 to March 2024. Of these, 46 men had pre- and postoperative semen analyses and sperm capacitation tests. The primary outcome measure was change in the sperm capacitation score (Cap-Score™; Androvia LifeSciences, Mountainside, NJ, USA). Secondary outcome measures included change in semen parameters, change in probability of generating a pregnancy (PGP), pregnancy rates, and live birth rates.RESULTSAmong all 46 patients, there was an improvement in median sperm concentration (21.9 vs 30.0 million/mL; P < 0.01), mean total motile sperm count (TMSC; 33.9 vs 49.5 million; P = 0.04), mean sperm capacitation as measured by Cap-Score (23.6% vs 27.7%; P < 0.01), and mean PGP (27.4% vs 34%; P < 0.01) after varicocelectomy. Of the 33 couples trying to conceive, 24 (72.7%) achieved a live birth or ongoing clinical pregnancy after varicocelectomy; however, 13 of these 24 couples (54.1%) utilised in vitro fertilisation. A normal postoperative sperm concentration and Cap-Score were associated with a 60% chance of achieving pregnancy via natural conception or intrauterine insemination (IUI).CONCLUSIONSignificant improvements in sperm concentration, TMSC, Cap-Score, and PGP were observed at 3 months after surgery. Patients with a normal post-varicocelectomy Cap-Score and semen concentration had the highest probability of conception naturally or through IUI.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"26 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144825474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Flexible ureterorenoscopy or extracorporeal shockwave lithotripsy in stone disease and bevacizumab for hereditary and sporadic papillary renal-cell cancer","authors":"","doi":"10.1111/bju.16886","DOIUrl":"10.1111/bju.16886","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"136 3","pages":"352-353"},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144825463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"September's reviewers of the month","authors":"","doi":"10.1111/bju.16887","DOIUrl":"10.1111/bju.16887","url":null,"abstract":"<p>Like most journals, BJUI relies on the hard work and dedication of its peer reviewers and we are grateful to them all. Each month the Editorial Team nominates peer reviewers whose reviews have stood out for their quality and timeliness and those selected as the best are highlighted on this page in recognition of their exceptional work.</p><p>Following certification, Dr Baard was appointed consultant urologist at Amsterdam UMC, where she continues to specialise in Endourology. She completed a Master's degree in Evidence-Based Practice in Health Care in 2022 and obtained the degree of Doctor of Philosophy in 2024. She initiated the Amsterdam UMC Expertise Center for UTUC, which was officially recognised by the Dutch Ministry of Health in 2021.</p><p>Dr Baard is a panel member of the EAU Guidelines Committee on UTUC and NMIBC. She is actively involved in academic teaching and research, with a focus on kidney-sparing treatment strategies and multidisciplinary care in UTUC.</p><p>Bill holds a PhD from the University of York and is a member of several national research leadership groups. He has served on the trial management or steering committees for landmark studies including STAMPEDE, RADICALS, POINTER-PC, and FOLLOW-UP, and is Chief Investigator for the PERSONAL study. His academic output includes over 100 peer-reviewed publications.</p><p>Bill is a member of the Clinical Reference Group for the National Prostate Cancer Audit and an invited advisor to NICE. In addition to his clinical and research work, he is Secondary Care Cancer Lead for the West Yorkshire and Harrogate Cancer Alliance.</p>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"136 3","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.16887","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144832469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative management of novel obesity and diabetes drugs: what the urologist needs to know.","authors":"Sabrina H Rossi,Vishal Patil,Sophie A Schenk,Grant D Stewart,James Armitage","doi":"10.1111/bju.16889","DOIUrl":"https://doi.org/10.1111/bju.16889","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"7 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144825477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.","authors":"Jonathan Olivier,Emily Vertosick,Luc Delobel,Thomas Bommelaere,Philippe Puech,Xavier Leroy,Andrew Vickers,Arnauld Villers","doi":"10.1111/bju.16884","DOIUrl":"https://doi.org/10.1111/bju.16884","url":null,"abstract":"OBJECTIVESTo determine if quantifying Gleason pattern 4 (GP4) is superior to Grade Group (GG) in predicting any and distant metastatic recurrence after radical prostatectomy (RP) for prostate cancer, and compare various GP4 quantification methods for predicting metastatic recurrence using preoperative targeted biopsy and magnetic resonance imaging (MRI) data.PATIENTS AND METHODSWe conducted a retrospective study of patients who underwent MRI-guided biopsies and RP from 2009 to 2018. Patients with GG 2-4 without GP5 disease on biopsy and/or RP specimen were included. The predictors compared were biopsy GG, percentage of GP4 in biopsy cores, millimetres of GP4 in biopsy cores, and volume of GP4 based on MRI lesion volume. These methods were also compared to the Cancer of the Prostate Risk Assessment (CAPRA), International Staging Collaboration for Cancer of the Prostate (STAR-CAP), European Association of Urology (EAU), and National Comprehensive Cancer Network (NCCN) risk classifications. The C-index for each model was calculated to evaluate discrimination performance.RESULTSA total of 446 patients were analysed, with a median follow-up of 6.9 years for patients without an event; 46 patients developed any metastasis. For any metastatic recurrence based on biopsy findings, the CAPRA score (C-Index = 0.72) showed the highest discrimination among risk scores, surpassing biopsy GG (C-Index = 0.70), but was outperformed by percentage GP4 (C-Index = 0.74), millimetres GP4 (C-Index = 0.77), and volume of GP4 (C-Index = 0.80).CONCLUSIONFor patients with GG 2-4 prostate cancer containing GP4, preoperative GP4 volume estimation using MRI and targeted biopsy outperforms Gleason scoring classification and standard risk scores in predicting any and distant metastatic recurrence. Further research is warranted on the best methods to quantify GP4 before incorporation in treatment decision-making.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"21 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term oncological outcomes of bladder cancer: a population-based study with a 25-year follow-up.","authors":"Linda Dey,Juhana Rautiola,Olof Akre,Lars Egevad,Abolfazl Hosseini,Reza Mehrazin,Jaakko Patrakka,Daniel Ranti,Lotta Renström-Koskela,John Sfakianos,Tomas Thiel,Per Henrik Vincent,Jane Yan,Gunnar Steineck,Peter Wiklund","doi":"10.1111/bju.16883","DOIUrl":"https://doi.org/10.1111/bju.16883","url":null,"abstract":"OBJECTIVETo describe the oncological outcomes for patients with newly diagnosed bladder cancer, as long-term oncological outcomes and natural history of different initial subtypes of diagnoses of bladder cancer are understudied.PATIENTS AND METHODSThis was a prospective, multicentre population-based cohort study, where newly diagnosed patients with bladder cancer from 1995 to 1996 in Stockholm County, Sweden were followed. The primary outcome was cancer-specific mortality (CSM), separately analysed for low-grade non-muscle-invasive bladder cancer (NMIBC Low), high-grade non-muscle-invasive bladder cancer (NMIBC High), and muscle-invasive bladder cancer (MIBC). We used cumulative incidence with competing risk to assess survival outcomes.RESULTSIn total, 526 patients were included, 396 had NMIBC. Out of 102 patients with T1, 37% died of bladder cancer during the 25-year follow-up. The rate of CSM for NMBIC Low was 3%, NMIBC High 26%, and MIBC 71%, respectively. For the operated patients with MIBC, the 5-year CSM was 39%. Of the 178 patients with NMIBC High, 22% progressed to MIBC, 10% had lymph node progression, and 17% progressed to metastatic disease during the follow-up. The main limitation of the study is that it was established 30 years ago.CONCLUSIONIn this population-based study, we found that patients with NMIBC High had a persistent risk of CSM up to 25 years from the initial diagnosis, more specifically in patients with T1 tumours. The study demonstrates the importance for optimal treatment for selective high-risk T1 patients with long life expectancy, and high risk of progression.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"69 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144796898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pioneering European telesurgery: first robot‐assisted radical prostatectomy with the Toumai® system","authors":"Edoardo Beatrici, Mario De Angelis, Sara Tamburini, Claudio Brancelli, Enrico Vecchio, Francesco Pepillo, Vincenzo Cavarra, Alessio Guidotti, Natali Rodriguez Peñaranda, Ruben De Groote, Edward Lambert, Geert De Naeyer, Alexandre Mottrie","doi":"10.1111/bju.16882","DOIUrl":"https://doi.org/10.1111/bju.16882","url":null,"abstract":"","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"27 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144792417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What has the COVID-19 pandemic taught us about safety of surgical wait times in urological oncology?","authors":"James P Blackmur,Chiara Re,Grant D Stewart","doi":"10.1111/bju.16881","DOIUrl":"https://doi.org/10.1111/bju.16881","url":null,"abstract":"OBJECTIVESTo review papers assessing the impact of surgical delay in relation to the COVID-19 pandemic, and evaluate what has been learnt about the safety of surgical waiting times in urological oncology.PATIENTS AND METHODSMedline and Web of Science were searched for studies published between 1 January 2020 and 1 November 2024. Studies included were those reporting treatment delay effects on surgical or oncological outcomes, or patient experience with reference to COVID-19. Priority was given to studies deriving their cohort after the start of the pandemic. Studies were also included in which the cohort was derived before the pandemic, but where recommendations were made on COVID-19 treatment delay. Data were extracted regarding duration of delay and authors' reported impact of delay on outcome (quantified, and simplified as negative/neutral/positive).RESULTSA total of 35 studies met the inclusion criteria. Fourteen studies included data collected after the start of the pandemic and 21 exclusively included cohorts derived prior to the pandemic but made recommendations about COVID-19-related treatment delays. Six studies on urothelial cancer reported negative clinical outcomes for delays between 2 weeks and 3 months, while three reported a neutral impact. Four studies on kidney cancer reported negative outcomes with 1-3-month delay, while two reported a neutral impact. Eleven studies on prostate cancer reported that a 3-12-month delay had neutral effects, while one reported negative outcomes. One study on penile cancer reported worse survival with delays in treatment. No studies on testicular cancer were identified. Five studies reported negative patient experience with delays, while one reported a positive patient experience.CONCLUSIONSFew studies have reported the impacts of COVID-19-related delayed treatment; this was a missed opportunity. While most prostate cancer treatment can be deferred up to 180 days, diagnostic cystoscopy, transurethral resection of bladder tumour and nephrectomy for cT2+ renal masses should be expedited to occur within 30 days. Treatment of cT1 renal masses, carcinoma invading bladder muscle, upper tract urothelial carcinoma and high-risk prostate cancer should commence within 90 days.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"21 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Direct in‐scope suction (DISS) ureteroscopy: techniques, outcomes and future directions","authors":"Parth U. Patel, Michael Uy, Casey Dauw, Wilson Sui, Jeffrey Plott, William W. Roberts, Khurshid R. Ghani","doi":"10.1111/bju.16871","DOIUrl":"https://doi.org/10.1111/bju.16871","url":null,"abstract":"ObjectiveTo provide an overview of direct in‐scope suction (DISS) ureteroscopy, an emerging technology that integrates suction directly into the ureteroscope with the aim of enhancing stone clearance, improving visualisation, and reducing intrarenal pressure during ureteroscopic stone surgery.MethodsWe performed a narrative review of the current literature and incorporated insights from the authors’ clinical experience using DISS ureteroscopy systems.ResultsDirect in‐scope suction ureteroscopes are either single‐channel or dual‐channel. With single‐channel ureteroscopes, irrigation must alternate with suction. A dual channel allows synchronous irrigation and suction. The suction can be applied continuously or intermittently (alternating with passive drainage). By actively managing intrarenal pressure, DISS may lower the risk of infectious complications and inadvertent laser injury. Unlike traditional ureteroscopy, some DISS systems may reduce the need for a ureteric access sheath (UAS). Early clinical data demonstrate that DISS offers stone‐free rates comparable to standard ureteroscopy, with no increase in major complications. However, performance varies across devices, with trade‐offs related to scope size, flexibility, suction power, and risk of clogging or collecting system collapse. Larger‐calibre DISS ureteroscopes may face deflection limitations in tight calyces as well as the need for a UAS. Refinements in single‐use platforms are addressing these challenges. DISS may be especially beneficial in patients with moderate‐to‐large stone burdens by enabling more efficient fragment evacuation and reducing the need for secondary procedures. Emerging technologies – such as integrated suction‐laser tools and pressure‐monitoring systems – promise to expand DISS capabilities further.ConclusionDirect in‐scope suction ureteroscopy represents a significant evolution in endourological practice by addressing key limitations of standard ureteroscopy, namely, fragment management, intrarenal pressure control, and visualisation. There remains a need for high‐quality level 1 evidence. With ongoing innovation, future DISS systems may offer complete stone clearance.","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"20 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144786819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}